Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

70 та иш

Иш: Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

  1. Fitting Linear Mixed-Effects Models Using <b>lme4</b>

    Douglas M. Bates, Martin Mächler, Benjamin M. Bolker +1

    Мақола201517 иқтибос
    ABI

  2. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

    Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4

    Мақола201011 иқтибос
    ABI

  3. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

    Shama D. Ahuja, David Ashkin, Monika Avendano +70

    Шарҳ мақола20127 иқтибос
    ABI

  4. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

    Andrew Nunn, Patrick Phillips, Sarah Meredith +16

    Мақола20196 иқтибос
    ABI

  5. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

    Alberto Piubello, Souleymane Hassane Harouna, Mahamadou Bassirou Souleymane +5

    Мақола20146 иқтибос
    ABI

  6. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries

    Arnaud Trébucq, V Schwoebel, Zacharie Kashongwe +15

    Мақола20176 иқтибос
    ABI

  7. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

    K. J. M. Aung, Armand Van Deun, Erik De Clercq +4

    Мақола20145 иқтибос
    ABI

  8. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

    Christopher Kuaban, J Noeske, Hans L. Rieder +3

    Мақола20155 иқтибос
    ABI

  9. Conducting Meta-Analyses in<i>R</i>with the<b>metafor</b>Package

    Wolfgang Viechtbauer

    Мақола20105 иқтибос
    ABI

  10. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

    Faiz Ahmad Khan, M Salim, Philipp du Cros +9

    Шарҳ мақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20174 иқтибос
    ABI

  11. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis

    Mayara Lisboa Bastos, Zhiyi Lan, Dick Menzies

    Шарҳ мақола20174 иқтибос
    ABI

  12. Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection

    Maryline Bonnet, Manuela Pardini, Francesca Meacci +14

    Мақола20114 иқтибос
    ABI

  13. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

    Mayara Lisboa Bastos, Hamidah Hussain, Karin Weyer +82

    Шарҳ мақола20144 иқтибос
    ABI

  14. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

    Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch +13

    Мақола20144 иқтибос
    ABI

  15. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

    Jonathan A C Sterne, Miguel A. Hernán, Barnaby C Reeves +32

    Мақола20164 иқтибос
    ABI

  16. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

    Nafees Ahmad, Shama D. Ahuja, Onno W. Akkerman +97

    Шарҳ мақола20184 иқтибос
    ABI

  17. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

    Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei +35

    Шарҳ мақола20203 иқтибос
    ABI

  18. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance

    J. Peter Cegielski, Ekaterina V. Kurbatova, Martie van der Walt +74

    Мақола20153 иқтибос
    ABI

  19. The binomial distribution of meta-analysis was preferred to model within-study variability

    Taye H. Hamza, Hans C. van Houwelingen, Theo Stijnen

    Мақола20072 иқтибос
    ABI

  20. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

    Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio +18

    Бошқа20162 иқтибос
    ABI

  21. Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes

    Laura Jean Podewils, Maria Tarcela Gler, Maria Imelda Quelapio +1

    Мақола20132 иқтибос
    ABI

  22. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

    Peter C. Austin

    Мақола20112 иқтибос
    ABI

  23. <b>mice</b>: Multivariate Imputation by Chained Equations in<i>R</i>

    Stef van Buuren, Karin Groothuis‐Oudshoorn

    Мақола20112 иқтибос
    ABI

  24. Multiple imputation using chained equations: Issues and guidance for practice

    Ian R. White, Patrick Royston, Angela Wood

    Мақола20102 иқтибос
    ABI

  25. Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis

    Kwok Chiu Chang, Chi Chiu Leung, Wing‐Wai Yew +4

    Мақола20122 иқтибос
    ABI